# Micardis® / MicardisPlus® Program for Therapy Optimization With Telmisartan in Cardiovascular Diseases (PROTEKT)

> **NCT02262637** · — · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 4814 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Micardis®
- **DRUG:** MicardisPlus®

## Key facts

- **NCT ID:** NCT02262637
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2003-09
- **Primary completion:** 2006-03
- **Final completion:** —
- **Target enrollment:** 4814 (ACTUAL)
- **Last updated:** 2014-10-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02262637

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02262637, "Micardis® / MicardisPlus® Program for Therapy Optimization With Telmisartan in Cardiovascular Diseases (PROTEKT)". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT02262637. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*